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Abstract
Background: Studies of genes involved in the absorption, distribution, metabolism, and excretion (ADME) of drugs
are crucial to the development of therapeutics in clinical medicine. Such data provide information that may improve
our understanding of individual differences in sensitivity or resistance to certain drugs, thereby helping to
avoid adverse drug reactions (ADRs) in patients and improve the quality of therapies. Here, we aimed to
analyse single nucleotide polymorphisms (SNPs) involved in the ADME of multiple drugs in Kazakhs from
Kazakhstan.
Results: A total of 158 SNPs involved in the ADME of various drugs were studied. We analysed 320 Kazakh
DNA samples using OpenArray genotyping. Of the 158 SNPs, 75 were not found in heterozygous or homozygous
variants. Comparative analysis among Kazakhs and world populations showed a fairly high percentage of population
differentiation.
Conclusion: These results provide further information for pharmacogenetic databases and may contribute to the
development of personalized approaches and safer therapies for the Kazakh population. Moreover, these data provide
insights into the different racial groups that may have contributed to the Kazakh population.
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Background
Current pharmacogenetic research includes the study of
genes involved in the absorption, distribution, metabolism,
and excretion (ADME) of drugs. These data may help cli-
nicians and researchers to understand individual differ-
ences in sensitivity or resistance to certain drugs, thereby
avoiding adverse drug reactions (ADRs) in patients and
improving the quality of therapies. Thus, pharmacogenetic
research has great practical value in the development of
personalised medicine. Moreover, pharmacogenetic stud-
ies contribute to our understanding of population genetics
because the frequencies of certain allelic variants may dif-
fer depending on the population. The people of Central
Asia are poorly understood from a population genetic
standpoint. However, studies in this field are on-going; the
Kazakh population has been studied by both domestic and
foreign scientists [1–4].
Kazakhs, one of the Turkic peoples of Central Asia, are
the main population of Kazakhstan. According to the Com-
mittee on Statistics of the Republic of Kazakhstan, about 11
million Kazakhs live in Kazakhstan, and about 3.5 million
Kazakhs live in regions neighbouring Kazakhstan and in
other regions (China, Russia, Uzbekistan, Turkmenistan,
Kyrgyzstan, west Mongolia, and Turkey) [5]. Kazakhs resid-
ing in the territory of Kazakhstan have an internal division
into three large groups, Elder or Senior (Uly), Middle or
Medium (Orta), and Lesser or Junior (Kishi) Zhuzes (or
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Hordes); historically, these three groups had demarcated
territories. Additionally, there were several tribes in each
Zhuz [6]. Every Kazakh knows to which tribe and Zhuz he
or she belongs, and representatives of the same tribe are
considered relatives as they have descended from a com-
mon ancestor. Therefore, according to the seven genera-
tions law, marriage between members of the same tribe is
only possible after seven generations from a common
ancestor [7].
Many genes associated with the ADME of drugs have
been identified. A team including representatives of the
pharmaceutical industry and an academic centre devel-
oped a core list of 32 ADME genes, which includes 184
markers that can be used to screen patients in clinical
trials. These data are available on the PharmaADME
website (http://pharmaadme.org/).
In this study, we aimed to analyse single nucleotide
polymorphisms (SNPs) involved in the ADME of mul-
tiple drugs in Kazakhs from Kazakhstan using an Open-
Array PGx Panel derived from the PharmaADME Core
Marker List.
Results
Allele and genotype frequency analysis
Allele and genotype frequency data were obtained for
158 SNPs (Additional file 1). Seventy-five out of the 158
SNPs included in this study were not found in heterozy-
gous or homozygous variants (Additional file 2). The al-
lele and genotype frequencies of the remaining 83 SNPs
are summarized in Table 1.
The correspondence of the distributions of genotype
frequencies to the Hardy-Weinberg equilibrium was
assessed using exact tests with a modified version of the
Markov-chain random walk algorithm [8] (р > 0.05).
Seven SNPs of the 83 (i.e., rs1799929 [p = 0.03],
rs2069514 [p = 0.02], rs1801280 [p = 0.01], rs12248560
[p = 0.00], rs2032582 G > A [p = 0.00], rs2032582 G > T
[p = 0.04], and rs2273697 [p = 0.04]) were not in Hardy-
Weinberg equilibrium.
Comparative analysis of allele frequencies
A comparative analysis of the allele frequency between
the Kazakh samples analysed here and HapMap pub-
lished data from 11 populations worldwide was carried
out (Table 2). A comparative analysis was performed
for those SNPs found in the Kazakh population in het-
erozygous or homozygous variants. hCV32287186,
hCV32407240, rs2069514, rs17885098, rs72552763,
rs35742686, rs72549350, rs5030867, rs55965422,
rs11572080, rs4986893, rs72559710, rs41291556,
rs55793712, rs35350960, rs55785340, rs2032582,
rs3892097, rs17878459, rs28399433, rs34059508,
rs41279188, rs4646438, rs17886522, rs12721655, and
rs1902023 frequency data are missing in the HapMap
database; therefore, these SNPs were not analysed, and
comparative analysis was carried out for 56 SNPs.
Exact tests of population differentiation with a signifi-
cance level of 0.05 were used [9]. No statistically sig-
nificant differences in the frequencies of rs8177507,
rs3740066, rs4986988, rs1799930, rs4646277, or
rs1801272 genotypes were found with any population
(p > 0.05).
Next, we performed a comparative analysis of the dif-
ferences in genotype frequencies among the Kazakh
population and data for world populations collected
from the HapMap database. For individuals of African
ancestry living in the southwest USA (ASW), only 35
SNPs of a total of 56 were analysed. The remaining data
for this population were no included in the HapMap
database. Twenty of these 35 SNPs were significantly dif-
ferent from those in the Kazakh population. These genes
encoded drug transporters (ABCB1, ABCC2, ABCG2,
SLC15A2, SLC22A2, SLCO1B1, SLCO1B3, and
SLCO2B1) and phase I (DPYD, CYP1A1, and CYP2B6)
and II (GSTP1, TPMT, UGT2B7, and UGT1A1) drug
metabolic enzymes. However, we found that there were
no significant differences in SNPs within genes belong-
ing to the acetyltransferase family (NAT2).
For Utah residents with Northern and Western European
ancestry from the CEPH collection (CEU), population ana-
lysis was carried out for 50 SNPs; 21 of these SNPs showed
significant differences compared with the Kazakh popula-
tion. These SNPs were found in genes encoding drug trans-
porters (ABCB1, ABCC2, SLC22A1, SLCO1B1, SLCO1B3,
and SLCO2B1) and phase I (CYP1A1, CYP2C8, CYP2C9,
and CYP2C19 ) and II (NAT2, GSTP1, and UGT1A1) drug
metabolic enzymes. SNPs in genes belonging to the solute
carrier family 15 (H+/peptide transporter) did not show dif-
ferences between the Kazakh and CEU populations.
Only 26 of 50 SNPs showed significant differences
among the Kazakh population and the Han Chinese
population in Beijing, China (CHB). For the Chinese
population in Metropolitan Denver, CO (CHD), popula-
tion analysis was carried out for 34 SNPs; 14 of these
SNPs showed significant differences from the Kazakh
population. Significant differences were also observed
for 24 of 51 SNPs in the Japanese population in Tokyo,
Japan (JPT), 23 of 30 SNP in the Luhya population in
Webuye, Kenya (LWK), 14 of 37 SNPs for the popula-
tion of Mexicans in Los Angeles, CA (MEX), 21 of 33
SNPs for the population of Maasai in Kinayawa, Kenya
(МKK), 17 of 33 SNPs the Tuscan population in Italy
(TSI), and 36 of 50 SNPs in the Yoruban population in
Ibadan, Nigeria (YRI).
For the Gujarati Indian population in Houston, TX
(GIH), population analysis was carried out for 38 SNPs;
23 of these SNPs showed significant differences from the
Kazakh population. Notably, comparative analyses of
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles)
# Assay name RS Number of
samples
Hardy-Weinberg equilibrium
p-value
Allele na Frequency Genotype nb Frequency
drug transporters ATP-binding cassette
1 ABCB1_C3435ntT rs1045642 280 0.39184 A 257 0.46 AA 55 0.20
G 303 0.54 AG 147 0.53
GG 78 0.8
2 ABCB1_T1236ntC rs1128503 278 0.72281 A 292 0.53 AA 75 0.27
G 264 0.47 AG 142 0.51
GG 61 0.22
3 ABCB1_2677nt G > T rs2032582 275 0.03713 C 308 0.56 СС 95 0.35
A 242 0.44 CA 118 0.43
AA 62 0.23
4 ABCB1_2677nt G > A rs2032582 240 0 C 409 0.85 СС 189 0.79
T 71 0.15 СT 31 0.13
TT 20 0.08
5 ABCC2_V417I rs2273697 279 0.03662 G 472 0.85 GG 195 0.70
A 86 0.15 GA 82 0.29
AA 2 0.01
6 ABCC2_I1324I rs3740066 279 0.32311 C 388 0.70 СС 131 0.47
T 170 0.30 СT 126 0.45
TT 22 0.08
7 ABCC2_-24C > T rs717620 292 0.36682 C 467 0.80 СС 184 0.63
T 117 0.20 СT 99 0.34
TT 9 0.03
8 ABCG2_ 421 nt C > A rs2231142 281 1 G 476 0.85 GG 201 0.72
T 86 0.15 GT 74 0.26
TT 6 0.02
Solute carrier family 15 (H+/peptide transporter)
9 SLC15A2_P409S rs1143671 288 1 T 315 0.55 TT 86 0.30
C 261 0.45 TC 143 0.50
CC 59 0.20
10 SLC15A2_R509K rs1143672 258 0.5314 A 282 0.55 AA 74 0.29
G 234 0.45 AG 134 0.52
GG 50 0.19
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles) (Continued)
11 SLC15A2_A284A rs2293616 287 0.5535 A 302 0.53 AA 82 0.29
G 272 0.47 AG 138 0.48
GG 67 0.23
12 SLC15A2_L350F rs2257212 277 0.90495 C 252 0.45 СС 58 0.21
T 302 0.55 СT 136 0.49
TT 83 0.30
Solute carrier family 22 (organic cation transporter)
13 SLC22A1_420del3 rs72552763 280 0.43952 GAT 512 0.91 GAT/GAT 235 0.84
del 48 0.09 GAT/del 42 0.15
del/del 3 0.01
14 SLC22A1_P283L rs4646277 269 1 C 525 0.98 СС 256 0.95
T 13 0.02 СT 13 0.05
TT 0 0.00
15 SLC22A1_P341L rs2282143 242 0.36537 C 463 0.96 СС 222 0.92
T 21 0.04 СT 19 0.08
TT 1 0.00
16 SLC22A1_M408V rs628031 272 0.79314 G 351 0.65 GG 112 0.41
A 193 0.35 GA 127 0.47
AA 33 0.12
17 SLC22A1_G465R rs34059508 283 0.06258 G 557 0.98 GG 275 0.97
A 9 0.02 GA 7 0.02
AA 1 0.00
18 SLC22A2_K432Q rs8177517 276 1 T 544 0.99 TT 268 0.97
G 8 0.01 TG 8 0.03
GG 0 0.00
19 SLC22A2_M165I rs8177507 289 1 C 569 0.98 СС 280 0.97
T 9 0.02 СT 9 0.03
TT 0 0.00
20 SLC22A2*4.1_S270A rs316019 267 0.376 C 495 0.93 CC 228 0.85
A 39 0.07 CA 39 0.15
AA 0 0.00
Solute carrier organic anion transporter family
21 SLCO1B1*1B_N130D rs2306283 267 0.53112 G 307 0.57 GG 91 0.34
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles) (Continued)
A 227 0.43 GA 125 0.47
AA 51 0.19
22 SLCO1B1*5_V174A rs4149056 243 0.14152 T 410 0.84 TT 176 0.72
C 76 0.16 TC 58 0.24
CC 9 0.04
23 SLCO1B3_699G > A rs7311358 265 0.13227 A 402 0.76 AA 157 0.59
G 128 0.24 GA 88 0.33
GG 20 0.08
24 SLCO1B3_334T > G rs4149117 254 0.85656 G 395 0.78 GG 154 0.61
T 113 0.22 GT 87 0.34
TT 13 0.05
25 SLCO2B1*3_S486F rs2306168 275 0.11608 C 461 0.84 СС 197 0.72
T 89 0.16 СT 67 0.24
TT 11 0.04
Phase II metabolizing
enzymes
Glutathione S-transferase pi 1
26 GSTP1_V105I rs1695 276 0.71558 C 437 0.79 AA 174 0.63
T 115 0.21 AG 89 0.32
GG 13 0.05
N-acetyltransferase
27 NAT1_884A > G rs55793712 294 1 A 584 0.99 AA 290 0.99
G 4 0.01 AG 4 0.01
GG 0 0.00
28 NAT1*11A-C g.-344C > T rs4986988 278 1 C 545 0.98 СС 267 0.96
T 11 0.02 СT 11 0.04
TT 0 0.00
29 NAT1*14_560G > A rs4986782 289 1 G 576 1.00 GG 287 0.99
A 2 0.00 GA 2 0.01
AA 0 0.00
30 NAT2*5_341T > C rs1801280 256 0.00661 C 136 0.27 СС 27 0.11
T 376 0.73 СT 82 0.32
TT 147 0.57
31 NAT2*6_590G > A rs1799930 269 0.62646 G 402 0.75 GG 148 0.55
A 136 0.25 GA 106 0.39
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles) (Continued)
AA 15 0.06
32 NAT2*7_857G > A rs1799931 278 1 A 62 0.11 AA 3 0.01
G 494 0.89 GA 56 0.20
GG 219 0.79
33 NAT2*11_481C > T rs1799929 267 0.03425 C 398 0.75 СС 155 0.58
T 136 0.25 СT 88 0.33
TT 24 0.09
34 NAT2*12_803A > G rs1208 272 0.18999 A 409 0.75 AA 158 0.58
G 135 0.25 AG 93 0.34
GG 21 0.08
35 NAT2*13_282C > T rs1041983 293 0.13049 C 368 0.63 СС 109 0.37
T 218 0.37 СT 150 0.51
TT 34 0.12
Thiopurine S-methyltransferase
36 TPMT*3B_460 G > A A154T rs1800460 249 1 C 492 0.99 CC 243 0.98
T 6 0.01 CT 6 0.02
TT 0 0.00
37 TPMT*3C_719A > G C240Y rs1142345 242 1 T 477 0.99 TT 235 0.97
C 7 0.01 TC 7 0.03
CC 0 0.00
UDP glucuronosyltransferase
38 UGT1A1*27_686C > A rs35350960 289 1 C 577 1.00 СС 288 1.00
A 1 0.00 CA 1 0.00
AA 0 0.00
39 UGT2B15*2_253G > T rs1902023 255 0.61468 A 281 0.55 AA 75 0.29
C 229 0.45 AC 131 0.51
CC 49 0.19
40 UGT1A1*6_211G > A rs4148323 288 0.66077 G 485 0.84 GG 205 0.71
A 91 0.16 GA 75 0.26
AA 8 0.03
41 UGT2B7*2b_-327G > A rs7662029 286 0.72247 A 307 0.54 AA 84 0.29
G 265 0.46 AG 139 0.49
GG 63 0.22
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles) (Continued)
42 UGT1A1*60_-3263 T > G rs4124874 274 0.52854 T 326 0.59 TT 94 0.34
G 222 0.41 TG 138 0.50
GG 42 0.15
43 UGT2B7*2a_-161C > T rs7668258 277 0.90334 T 295 0.53 TT 79 0.29
C 259 0.47 TC 137 0.49
CC 61 0.22
Dihydropyrimidine dehydrogenase
Phase I metabolizing
enzymes
44 DPYD*2A_IVS14 + 1G > A rs3918290 288 1 C 575 1.00 СС 287 1.00
T 1 0.00 СT 1 0.00
TT 0 0.00
45 DPYD*7_delTACT hCV32287186 279 1 ATGA 551 0.99 ATGA/
ATGA
272 0.97
del 7 0.01 ATGA/del 7 0.03
del/del 0 0.00
46 DPYD*9A_C29R rs1801265 268 0.8213 A 450 0.84 AA 188 0.70
G 86 0.16 AG 74 0.28
GG 6 0.02
Cytochrome P450
47 CYP1A1*2 g.2455A > G rs1048943 279 0.20473 T 463 0.83 TT 195 0.70
C 95 0.17 TC 73 0.26
CC 11 0.04
48 CYP1A1*4 g.2453C > A rs1799814 282 0.17395 G 549 0.97 GG 268 0.95
T 15 0.03 GT 13 0.05
TT 1 0.00
49 CYP1A1*9 g.2461C > T rs41279188 294 1 G 587 1.00 GG 293 1.00
A 1 0.00 GA 1 0.00
AA 0 0.00
50 CYP1A2*1C g.-3860G > A rs2069514 259 0.01548 G 437 0.84 GG 190 0.73
A 81 0.16 GA 57 0.22
AA 12 0.05
51 CYP1A2*1 F g.-163C > A rs762551 297 0.60371 A 394 0.66 AA 133 0.45
C 200 0.34 CA 128 0.43
CC 36 0.12
52 CYP1A2*1 K g.-729C > T rs12720461 294 1 C 587 1.00 СС 293 1.00
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles) (Continued)
T 1 0.00 СT 1 0.00
TT 0 0.00
53 CYP2A6*2 g.1799 T > A rs1801272 261 1 A 515 0.99 AA 254 0.97
T 7 0.01 AT 7 0.03
TT 0 0.00
54 CYP2A6*9 g.-48 T > G rs28399433 261 0.06641 A 460 0.88 AA 206 0.79
C 62 0.12 AC 48 0.18
CC 7 0.03
55 CYP2B6*6 g.15631G > T rs3745274 232 0.40492 G 339 0.73 GG 121 0.52
T 125 0.27 GT 97 0.42
TT 14 0.06
56 CYP2B6*8 g.13072A > G rs12721655 265 1 A 529 1.00 AA 264 1.00
G 1 0.00 AG 1 0.00
GG 0 0.00
57 CYP2B6*16 g. 21011 T > C rs28399499 299 1 T 583 0.97 TT 284 0.95
C 15 0.03 TC 15 0.05
CC 0 0.00
58 CYP2C8*2 g.11054A > T rs11572103 275 1 T 548 1.00 TT 273 0.99
A 2 0.00 TA 2 0.01
AA 0 0.00
59 CYP2C8*3 g.30411A > G rs10509681 278 1 T 530 0.95 TT 252 0.91
C 26 0.05 TC 26 0.09
CC 0 0.00
60 CYP2C8*3 g.2130G > A rs11572080 270 1 C 512 0.95 СС 242 0.90
T 28 0.05 СT 28 0.10
TT 0 0.00
61 CYP2C8*4 g.11041C > G rs1058930 282 1 G 557 0.99 GG 275 0.98
C 7 0.01 GC 7 0.02
CC 0 0.00
62 CYP2C9*2 g.3608C > T rs1799853 277 1 C 527 0.95 СС 250 0.90
T 27 0.05 СT 27 0.10
TT 0 0.00
63 CYP2C9*3 g.42614A > C rs1057910 247 0.37469 A 457 0.93 AA 210 0.85
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles) (Continued)
C 37 0.07 AC 37 0.15
CC 0 0.00
64 CYP2C9*12 g.50338C > T rs9332239 282 1 C 535 0.95 СС 253 0.90
T 29 0.05 СT 29 0.10
TT 0 0.00
65 CYP2C19 rs17878459 239 1 G 475 0.99 GG 236 0.99
C 3 0.01 GC 3 0.01
CC 0 0.00
66 CYP2C19 g.99C > T rs17885098 259 0.14454 C 50 0.10 СС 0 0.00
T 468 0.90 СT 50 0.19
TT 209 0.81
67 CYP2C19*2 g.19154G > A (splicing defect) rs4244285 265 0.28264 G 439 0.83 GG 179 0.68
A 91 0.17 GA 81 0.31
AA 5 0.02
68 CYP2C19*2 g.80160C > T rs3758580 283 0.3245 C 462 0.82 СС 191 0.67
T 104 0.18 СT 80 0.28
TT 12 0.04
69 CYP2C19*3 g.17948G > A rs4986893 278 1 G 533 0.96 GG 255 0.92
A 23 0.04 GA 23 0.08
AA 0 0.00
70 CYP2C19*3B g.87313A > C rs17886522 289 1 A 547 0.95 AA 258 0.89
C 31 0.05 AC 31 0.11
CC 0 0.00
71 CYP2C19*8 g.12711 T > C rs41291556 119 1 T 237 1.00 TT 118 0.99
C 1 0.00 TC 1 0.01
CC 0 0.00
72 CYP2C9*11 g.42542C > T rs28371685 277 1 C 553 1.00 СС 276 1.00
T 1 0.00 СT 1 0.00
TT 0 0.00
73 CYP2C19*17 g.-806C > T rs12248560 279 0.00451 C 494 0.89 СС 224 0.80
T 64 0.11 СT 46 0.16
TT 9 0.03
74 CYP2D6*3 g.2549delA rs35742686 280 1 T 545 0.97 T/T 265 0.95
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Table 1 Allele frequency and genotype distribution in the Kazakh population (а number of chromosomes; b number of alleles) (Continued)
del 15 0.03 T/del 15 0.05
del/del 0 0.00
75 CYP2D6*4 g.1846G > A rs3892097 290 0.42114 C 507 0.87 СС 223 0.77
T 73 0.13 СT 61 0.21
TT 6 0.02
76 CYP3A5*5 g.12952 T > C rs55965422 272 1 A 525 0.97 AA 253 0.93
G 19 0.03 AG 19 0.07
GG 0 0.00
77 CYP2D6*7 g.2935A > C rs5030867 264 1 T 527 1.00 TT 263 1.00
G 1 0.00 TG 1 0.00
GG 0 0.00
78 CYP2D6*9 g.2613_2615delAGA rs72549350 296 1 TCT 570 0.96 TCT/TCT 274 0.93
del 22 0.04 TCT/del 22 0.07
del/del 0 0.00
79 CYP2D6*40 g.1863_1864ins(TTTCGCCCC)2 hCV32407240 292 1 - 577 0.99 −/−' 285 0.98
ins 7 0.01 Ins/- 7 0.02
Ins/Ins 0 0.00
80 CYP2E1*2 g.1132G > A rs72559710 290 1 G 577 0.99 GG 287 0.99
A 3 0.01 GA 3 0.01
AA 0 0.00
81 CYP3A4*2 g.15713 T > C rs55785340 273 1 A 540 0.99 AA 267 0.98
G 6 0.01 AG 6 0.02
GG 0 0.00
82 CYP3A4*6 c.830_831insA rs4646438 276 1 - 551 1.00 −/− 275 1.00
insA 1 0.00 -/insA 1 0.00
insA/insA 0 0.00
drug targets Vitamin K epoxide reductase complex
83 VKORC1 rs8050894 268 0.43311 G 337 0.63 GG 109 0.41
C 199 0.37 GC 119 0.44
CC 40 0.15
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Table 2 A comparative analysis of the allele frequency between Kazakh population (our data) and world’s populations (HapMap data)
# Assay name RS Exact test of population differentiation (P value)
ASW CEU CHB CHD GIH JPT LWK MEX MKK TSI YRI
drug transporters ATP-binding cassette
1 ABCB1_C3435ntT rs1045642 0.00 +
−0.00
0.01 +
−0.00
0.07 +
−0.00
0.06 +
−0.0038
0.00 +
−0.00
0.80 +
−0.01
0.94 +
−0.00
0.00 + −0.00 0.70 +
−0.01
0.00 +
−0.00
2 ABCB1_T1236ntC rs1128503 0.00 +
−0.00
0.08 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.25 +
−0.01
0.35 +
−0.01
0.00 +
−0.00
0.39 +
−0.01
0.00 + −0.00 0.06 +
−0.00
0.00 +
−0.00
3 ABCB1_2677nt G > T rs2032582 0.00 +
−0.00
0.01 +
−0.00
0.69 +
−0.01
0.01 +
−0.00
0.03 +
−0.00
0.99 +
−0.00
0.00 +
−0.00
0.02 +
−0.00
0.00 + −0.00 0.02 +
−0.00
4 ABCC2_V417I rs2273697 0.08 +
−0.00
0.00 +
−0.00
0.07 +
−0.0057
0.13 +
−0.01
0.00 +
−0.00
0.40 +
−0.01
0.14 +
−0.00
0.26 +
−0.01
0.00 + −0.00 0.00 +
−0.00
0.02 +
−0.00
5 ABCC2_I1324I rs3740066 0.58 +
−0.01
0.78 +
−0.0050
0.69 +
−0.01
0.82 +
−0.00
6 ABCC2_-24C > T rs717620 0.00 +
−0.00
0.54 +
−0.01
0.87 +
−0.0056
0.67 +
−0.01
0.00 +
−0.00
0.55 +
−0.01
0.00 +
−0.00
0.41 +
−0.01
0.00 + −0.00 1.00 +
−0.00
0.00 +
−0.00
7 ABCG2_ 421 nt C > A rs2231142 0.00 +
−0.00
0.36 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.01 +
−0.00
0.00 +
−0.00
0.35 +
−0.01
0.00 + −0.00 0.00 +
−0.00
0.00 +
−0.00
Solute carrier family 15 (H+/peptide transporter)
8 SLC15A2_P409S rs1143671 0.04 +
−0.00
0.09 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.01 +
−0.00
0.00 +
−0.00
0.03 + −0.00 0.00 +
−0.00
0.67 +
−0.01
9 SLC15A2_R509K rs1143672 0.38 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.62 +
−0.01
10 SLC15A2_A284A rs2293616 0.11 +
−0.01
0.19 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.08 +
−0.01
0.00 +
−0.00
0.09 +
−0.0073
0.00 +
−0.00
0.57 +
−0.01
11 SLC15A2_L350F rs2257212 0.04 +
−0.00
0.09 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.01 +
−0.00
0.00 +
−0.00
0.05 + −0.00 0.00 +
−0.00
0.67 +
−0.01
Solute carrier family 22 (organic cation transporter)
12 SLC22A1_P283L rs4646277 0.20 +
−0.00
0.55 +
−0.01
13 SLC22A1_P341L rs2282143 0.82 +
−0.00
0.04 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.11 +
−0.00
0.00 +
−0.00
0.12 +
−0.01
0.63 +
−0.00
0.70 + −0.00 0.03 +
−0.00
14 SLC22A1_M408V rs628031 0.47 +
−0.01
0.17 +
−0.01
0.00 +
−0.00
0.26 +
−0.01
0.91 +
−0.00
0.00 +
−0.00
0.09 +
−0.00
0.00 +
−0.00
0.07 + −0.00 0.61 +
−0.01
0.02 +
−0.00
15 SLC22A2_K432Q rs8177517 1.00 +
−0.00
0.37 +
−0.00
0.60 +
−0.01
0.61 +
−0.0026
0.00 +
−0.00
0.76 + −0.01 0.00 +
−0.00
16 SLC22A2_M165I rs8177507 1.00 +
−0.00
0.29 +
−0.00
0.47 +
−0.00
1.00 +
−0.00
0.67 +
−0.01
0.37 +
−0.01
17 SLC22A2*4.1_S270A rs316019 0.00 +
−0.00
0.21 +
−0.01
0.09 +
−0.01
0.26 +
−0.00
0.02 +
−0.00
0.16 +
−0.00
0.00 +
−0.00
1.00 +
−0.00
0.01 + −0.00 0.01 +
−0.00
0.00 +
−0.00
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Table 2 A comparative analysis of the allele frequency between Kazakh population (our data) and world’s populations (HapMap data) (Continued)
Solute carrier organic anion transporter family
18 SLCO1B1*1B_N130D rs2306283 0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.66 +
−0.01
0.21 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.00 + −0.00 0.00 +
−0.00
0.00 +
−0.00
19 SLCO1B1*5_V174A rs4149056 0.01 +
−0.00
0.26 +
−0.01
0.54 +
−0.01
0.70 +
−0.01
0.00 +
−0.00
0.39 +
−0.00
0.00 +
−0.00
0.16 +
−0.01
0.28370 +
−0.0066
0.08 +
−0.00
0.00 +
−0.00
20 SLCO1B3_699G > A rs7311358 0.01 +
−0.00
0.93 +
−0.00
0.12 +
−0.02
0.00 +
−0.00
21 SLCO1B3_334T > G rs4149117 0.00 +
−0.00
0.04 +
−0.0020
0.28 +
−0.01
0.84 +
−0.00
0.00 +
−0.00
0.13 +
−0.01
0.00 +
−0.00
0.06 +
−0.0041
0.00 + −0.00 0.01 +
−0.00
0.00 +
−0.00
22 SLCO2B1*3_S486F rs2306168 0.00 +
−0.00
0.00 +
−0.00
0.13 +
−0.00
0.06 +
−0.00
0.23 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
1.00 +
−0.00
0.00 + −0.00 0.00 +
−0.00
0.00 +
−0.00
phase II metabolizing
enzymes
Glutathione S-transferase pi 1
23 GSTP1_V105I rs1695 0.00 +
−0.00
0.00 +
−0.00
0.76 +
−0.00
0.57 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 + −0.00 0.02 +
−0.00
0.00 +
−0.00
N-acetyltransferase
24 NAT1*11A-C g.-344C > T rs4986988 0.20 +
−0.01
0.31 +
−0.00
0.31 +
−0.00
0.74 +
−0.00
0.31 +
−0.01
0.70 +
−0.00
0.23 + −0.01 0.15 +
−0.01
0.20 +
−0.01
25 NAT1*14_560G > A rs4986782 0.13 +
−0.01
1.00 +
−0.00
1.00 +
−0.00
0.55 +
−0.00
1.00 +
−0.00
26 NAT2*5_341T > C rs1801280 0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.80 +
−0.00
27 NAT2*6_590G > A rs1799930 0.34 +
−0.01
0.14 +
−0.00
0.08 +
−0.01
0.98 +
−0.00
0.03 +
−0.00
0.35 +
−0.01
0.48 +
−0.01
0.29 +
−0.01
0.31 + −0.01 0.48 +
−0.01
0.93 +
−0.00
28 NAT2*7_857G > A rs1799931 0.16 +
−0.00
0.00 +
−0.00
0.02 +
−0.00
0.09 +
−0.00
0.17 +
−0.01
0.14 +
−0.00
0.00 +
−0.00
0.12 +
−0.00
0.01 + −0.00 0.00 +
−0.00
0.00 +
−0.00
29 NAT2*11_481C > T rs1799929 0.89 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.13 +
−0.00
0.00 +
−0.00
0.04 +
−0.00
0.12 +
−0.01
0.00 + −0.00 0.00 +
−0.00
0.02 +
−0.00
30 NAT2*12_803A > G rs1208 0.08 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 + −0.00 0.00 +
−0.00
0.01 +
−0.00
31 NAT2*13_282C > T rs1041983 0.10 +
−0.00
0.03 +
−0.00
0.65 +
−0.01
0.27 +
−0.01
0.54 +
−0.01
0.03 +
−0.00
0.09 +
−0.01
0.47 +
−0.01
0.45 + −0.01 0.15 +
−0.01
0.00 +
−0.00
Thiopurine S-methyltransferase
32 TPMT*3C_719A > G C240Y rs1142345 0.00 +
−0.00
0.36 +
−0.01
0.68 +
−0.00
0.31 +
−0.01
0.50 +
−0.00
0.73 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.57 + −0.00 0.69 +
−0.00
0.05 +
−0.00
UDP glucuronosyltransferase
33 UGT1A1*6_211G > A rs4148323 0.00 +
−0.00
0.02 +
−0.00
0.62 +
−0.01
0.00 +
−0.00
0.73 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
34 UGT2B7*2b_-327G > A rs7662029 0.00 +
−0.00
0.43 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.04 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 + −0.00 0.34 +
−0.01
0.00 +
−0.00
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Table 2 A comparative analysis of the allele frequency between Kazakh population (our data) and world’s populations (HapMap data) (Continued)
35 UGT1A1*60_-3263 T > G rs4124874 0.00 +
−0.00
0.35 +
−0.01
0.01 +
−0.00
0.30 +
−0.01
0.00 +
−0.00
0.18 +
−0.01
0.00 +
−0.00
0.05 +
−0.00
0.00 + −0.00 0.87 +
−0.00
0.00 +
−0.00
36 UGT2B7*2a_-161C > T rs7668258 0.00 +
−0.00
0.57 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.06 +
−0.01
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 + −0.00 0.39 +
−0.01
0.00 +
−0.00
phase I metabolizing
enzymes Dihydropyrimidine dehydrogenase
37 DPYD*2A_IVS14 + 1G > A rs3918290 0.04 +
−0.00
38 DPYD*9A_C29R rs1801265 0.00 +
−0.00
0.86 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.02 +
−0.00
0.00 + −0.00 0.02 +
−0.00
0.00 +
−0.00
Cytochrome P450
39 CYP1A1*2 g.2455A > G rs1048943 0.00 +
−0.00
0.00 +
−0.00
0.08 +
−0.01
0.07 +
−0.01
0.07 +
−0.00
0.28 +
−0.01
0.05 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
40 CYP1A1*4 g.2453C > A rs1799814 0.80 +
−0.00
0.33 +
−0.00
0.00 +
−0.00
0.39 +
−0.00
0.75 +
−0.00
0.28 +
−0.00
41 CYP1A2*1 F g.-163C > A rs762551 0.67 +
−0.00
0.31 +
−0.01
0.63 +
−0.01
0.39 +
−0.01
0.00 +
−0.00
0.25 +
−0.01
0.00 +
−0.00
0.20 +
−0.01
0.00 + −0.00 0.60 +
−0.01
0.05 +
−0.01
42 CYP1A2*1 K g.-729C > T rs12720461 0.40 +
−0.00
43 CYP2A6*2 g.1799 T > A rs1801272 0.05 +
−0.00
0.60 +
−0.00
0.62 +
−0.00
0.37 +
−0.00
44 CYP2B6*6 g.15631G > T rs3745274 0.94 +
−0.00
0.88 +
−0.00
0.03 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.03 +
−0.00
0.41 +
−0.01
0.61 +
−0.00
0.01 + −0.00 0.72 +
−0.00
0.00 +
−0.00
45 CYP2B6*16 g. 21011 T > C rs28399499 0.01 +
−0.00
0.00 +
−0.00
0.48 +
−0.01
0.16 + −0.00 0.00 +
−0.00
46 CYP2C8*2 g.11054A > T rs11572103 1.00 +
−0.00
1.00 +
−0.00
1.00 +
−0.00
0.00 +
−0.00
47 CYP2C8*3 g.30411A > G rs10509681 1.00 +
−0.00
0.00 +
−0.00
0.04 +
−0.00
0.22 +
−0.01
0.03 +
−0.00
0.04 +
−0.00
0.12 + −0.01 0.00 +
−0.00
0.01 +
−0.00
48 CYP2C8*4 g.11041C > G rs1058930 0.69 +
−0.00
49 CYP2C9*2 g.3608C > T rs1799853 0.03 +
−0.00
0.02 +
−0.00
0.02 +
−0.00
0.01 +
−0.00
50 CYP2C9*3 g.42614A > C rs1057910 0.08 +
−0.01
0.42 +
−0.01
0.37 +
−0.01
0.39 +
−0.01
0.02 +
−0.00
0.02 +
−0.00
0.51 +
−0.00
0.72 +
−0.01
0.00 +
−0.00
51 CYP2C9*12 g.50338C > T rs9332239 0.01 +
−0.00
0.02 +
−0.00
0.02 +
−0.00
0.01 +
−0.00
52 CYP2C19*2 g.19154G > A
(splicing defect)
rs4244285 0.10 +
−0.01
0.03 +
−0.00
0.03 +
−0.00
0.29 +
−0.01
53 CYP2C19*2 g.80160C > T rs3758580
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Table 2 A comparative analysis of the allele frequency between Kazakh population (our data) and world’s populations (HapMap data) (Continued)
0.40 +
−0.01
0.01 +
−0.00
0.05 +
−0.00
0.58 +
−0.00
54 CYP2C9*11 g.42542C > T rs28371685 0.42 +
−0.00
55 CYP2C19*17 g.-806C > T rs12248560 0.00 +
−0.00
0.04 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
drug targets Vitamin K epoxide reductase complex
56 VKORC1 rs8050894 0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
0.00 +
−0.00
Significance level = 0.05
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rs12720461, rs28371685, rs1058930, and rs3918290 were
carried out only for the GIH population because fre-
quency data in the HapMap database were only available
for this population. Of these SNPs, only rs3918290
showed a significant difference from the Kazakh
population.
If we compare the ratios of significantly different SNPs
with the amount of data (i.e., the number of SNPs that
were analysed) for each population, the YRI population
showed the greatest differences compared with the
Kazakh population. However, similar to the CEU popula-
tion, statistically significant differences for SNPs of genes
belonging to the solute carrier family 15 (H+/peptide
transporter) were not found.
The SNPs rs8177507, rs3740066, rs4986988, rs4986782,
rs12720461, rs1799930, rs28371685, rs4646277, rs1801272,
rs11572103, and rs1058930 showed no significant differ-
ences with any of the compared populations, suggesting
that the power of the study (320 DNA samples) may be
insufficient.
Linkage disequilibrium (LD) analysis for the Kazakh
population
Using Haploview 4.2 software, LD statistics results for
the Kazakh population were obtained (Fig. 1). For block
generations, the Confidence Intervals default algorithm
was used. We selected SNPs that were consistent with
Hardy-Weinberg equilibrium and ignored those with
minor allele frequencies (MAFs) of less than 0.05. As a
result, four haplotype blocks were defined: two blocks
consisting of two SNPs, i.e., rs7662029 and rs7668258
(block 3, chromosome 4) and rs4149117 and rs7311358
(block 2, chromosome 12); one block consisting of three
SNPs, i.e., rs2293616, rs2257212, and rs1143671 (block
4, chromosome 3); and one block consisting of five
SNPs, i.e., rs1041983, rs1801280, rs1799929, rs1799930,
and rs1208 (block 1, chromosome 8). The strongest LDs
were found for rs2293616–rs2257212, rs2293616–
rs1143671, rs2257212–rs1143671, rs7662029–rs7668258,
rs4986893–rs17886522, and rs10509681–rs11572080 in
the Kazakh population. The haplotype frequencies in the
studied population are presented in Table 3.
The crossover percentage matrix showed that the
highest value had the pattern GA-AT (block 2–block 3;
40.4 %). Additionally, 34.5 % of all samples had the pat-
tern GA-GC (block 2–block 3), 28.5 % had the pattern
AT-ATT GC (block 3–block 4), and 26.9 % had the pat-
tern CTCGA-GA (block 1–block 2).
Tag-SNP analysis was also carried out using the ag-
gressive tagging strategy (r2 threshold: 0.8, logarithm
(base 10) of odds [LOD] threshold: 3.0, minimum dis-
tance between tags: 0 kb). The analysis results are shown
in Table 4. We found that rs1143672 was a tag-SNP for
block 4. Therefore, it was likely that block 4 was formed
by four SNPs, i.e., rs2293616, rs2257212, rs1143671, and
rs1143672, rather than three SNPs.
Comparative analysis of haplotype frequency
Next, we carried out a comparative analysis of the
haplotype frequencies of the samples from the Kazakh
population and published data from the HapMap
database, including 11 worldwide populations. All of
the SNPs described in Fig. 1 were used for analysis;
however, not all of these SNPs were present in the
HapMap database. For block generations, the Confi-
dence Intervals default algorithm was used (Haplo-
view 4.2, MAF < 0.05). Block generation results for all
11 population are presented in Additional file 3. From
these data, only the CEU population formed a block
in the NAT2 gene that was similar to that in the
Fig. 1 LD SNP plot. The LD is displayed according to standard colour schemes, with bright red for very strong LD (LOD > 2, D’ = 1), light red
(LOD > 2, D’ < 1) and blue (LOD < 2, D’ = 1) for intermediate LD, and white (LOD < 2, D’ < 1) for no LD
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Kazakh population, consisting of rs1041983,
rs1801280, rs1799929, rs1799930, and rs1208. The
CEU block contained seven haplotypes, whereas that
in the Kazakh population contained only six haplo-
types; additionally, the frequencies were different
(Table 5). The GIH, LWK, MKK, and TSI populations
generated blocks consisting of only four SNPs:
rs1041983, rs1799929, rs1799930, and rs1208, whereas
the MEX and YRI populations generated blocks con-
sisting of three SNPs (rs1041983, rs1799929, and
rs1799930). The JPT population generated blocks
consisting of two SNPs (rs1041983 and rs1799930).
Blocks were not generated by ASW, CHB, or CHD
populations. Additionally, CEU, CHB, JPT, and YRI
populations generated blocks similar to those of the
Kazakh population, consisting of two SNPs
(rs4149117 and rs7311358) in the SLCO1B3 gene
(Additional file 3). These populations had four haplo-
types that differed in frequency (Fig. 2). The highest
frequency of haplotype GA was found in the CEU
population (0.852), whereas the lowest frequency of
haplotype GA was found in the YRI population
(0.342). The value closest to that in the Kazakh popu-
lation for haplotype GA (0.758) was found in the
CHB population (0.710). The highest and lowest fre-
quencies of haplotype TG were found in the YRI
Table 3 Haplotype frequencies in the Kazakh population
Locus Haplotype Frequencies
Block 1
rs1041983|rs1801280|rs1799929|rs1799930|rs1208
NAT2*13/ NAT2*5/ NAT2*11/ NAT2*6/ NAT2*12
CCTGG 0.236
CCCGG 0.012
TTCAA 0.248
TTCGA 0.113
CTCGA 0.363
CCTGA 0.016
Block2
rs4149117|rs7311358
SLCO1B3_334T > G/ SLCO1B3_699G > A
TG 0.213
GG 0.030
GA 0.758
Block 3
rs7662029|rs7668258
UGT2B7*2b/ UGT2B7*2a
GC 0.464
AT 0.525
Block 4
rs2293616|rs2257212|rs1143671
SLC15A2_A284A/ SLC15A2_L350F/ SLC15A2_P409S
GCC 0.449
ATT 0.546
Table 4 Tag SNPs
# Test Alleles Captured Chromosome
1 rs1143672 rs2257212. rs2293616. rs1143671. rs1143672 3
2 rs72558190 rs72558190. rs41291556. rs28371686 10
3 hCV32407240 rs72549346. rs5030655. hCV32407240 22
4 rs1208 rs1801280. rs1208. rs1799929 8
5 rs4986893 rs17886522. rs4986893 10
6 rs4149117 rs4149117. rs7311358 12
7 rs9332239 rs9332239. hCV72649992 10
8 rs1805158 rs1805158. rs5030839 8
9 rs10509681 rs10509681. rs11572080 10
10 rs1058930 rs1058930. rs11572103 10
11 rs3758580 rs4244285. rs3758580 10
12 rs41279854 rs10264272. rs41279854 7
13 rs55640102 rs55640102. rs9332131 10
14 rs8177507 rs55918055. rs8177507 6
15 rs7668258 rs7662029. rs7668258 4
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(0.658) and CEU (0.148) populations. The value clos-
est to the Kazakh population for haplotype TG
(0.213) was found in the CHB population (0.265). The
TA haplotype was found only in the JPT (0.038) and
CHB (0.025) populations, and the GG haplotype was
found only in the Kazakh population (0.030). The rest
of the analysed populations did not generate blocks.
Kazakh population block, consisting of rs7662029 and
rs7668258 in the UGT2B7 gene, was found in all 11 popu-
lations (Additional file 3). The highest and lowest frequen-
cies of haplotype GC were found in the YRI (0.824) and
CEU (0.490) populations, and the highest and lowest fre-
quencies of haplotype AT were found in the CEU (0.510)
and AWS (0.176) populations, respectively. The GC (0.464)
Table 5 Haplotype analysis results of rs1041983, rs1801280, rs1799929, rs1799930 and rs1280 in NAT2 (chromosome 8)
Population CEU GIH JPT LWK MEX MKK TSI YRI KAZ
CCTGG 0.392 0.236
TTCAA 0.294 0.248
CTCGA 0.206 0.363
CCTGA 0.040 0.016
CCCGG 0.029 0.012
CTCGG 0.020
TTCGA 0.020 0.113
CCGA 0.205 0.086 0.075 0.233
CCAA 0.014
TCAA 0.352 0.279 0.301 0.284
CTGG 0.322 0.322 0.451 0.443
TCGA 0.062 0.159 0.112 0.017
CCGG 0.059 0.139 0.061 0.011
CG 0.679
TA 0.238
TG 0.083
CTG 0.375
CCG 0.320
TCA 0.185
TCG 0.120
TTC 0.478
CTC 0.239
CCT 0.186
CCC 0.097
0 0.2 0.4 0.6 0.8 1 1.2
CEU
CHB
JPT
YRI
KAZ
GA
TG
TA
GG
Fig. 2 Haplotype analysis results of rs4149117 and rs7311358 in the SLCO1B gene (chromosome 12)
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and AT (0.525) haplotype frequencies in the Kazakh popu-
lation were close to the respective frequencies in the CEU
population (Fig. 3).
All 11 populations generated blocks in the SLC15A2
gene (Additional file 3). However, these blocks contained
different numbers of SNPs. The CEU, CHB, JPT, and
YRI populations generated blocks consisting of four
SNPs: rs2293616, rs2257212, rs1143671, and rs1143672.
The blocks of the other analysed populations consisted
of three SNPs: rs2293616, rs2257212, and rs1143671.
The highest and lowest frequencies of haplotype GCC
were found in the MEX (0.728) and CEU (0.253) popula-
tions (Fig. 4). The highest and lowest frequencies of
haplotype GCCG were found in the CEU (0.540) and
JPT (0.233) populations. The highest frequencies of hap-
lotypes ATT and ATTA were found in the CHD (0.747)
and CHB (0.750) populations, whereas the lowest fre-
quencies of haplotypes ATT and ATTA were found in
the GIH (0.295) and CEU (0.450) populations.
If we take into account rs1143672 tagging analysis re-
sults of the Kazakh population and assume that block 4
consisted of four SNPs, the frequency of the GCCG
haplotype was 0.459, and that of ATTA was 0.537. These
values were nearly identical to the results of the YRI
population.
Discussion
In this study, we examined the frequencies of specific
SNPs in the Kazakh population and compared the re-
sults with those in the HapMap database for 11 other
populations throughout the world. The results showed a
fairly high percentage of population differentiation, pro-
viding insights into the different racial groups that may
have contributed to the Kazakh population.
The Kazakh population is an interesting model in
population genetics, and the process through which the
Kazakh population formed is poorly understood.
However, some scientists believe that the Kazakh popu-
lation was formed by the mixing of the Asian and Cau-
casoid populations [6] owing to the observation that
there are Kazakh individuals who have distinctive Asian
and/or Caucasoid traits. Additionally, the Kazakh people
are divided into three Zhuzes and further divided into
distinct tribes in each Zhuz. The historical division into
Zhuzes could be argued on the basis of the different ori-
gins of each Zhuz; this could explain the different fre-
quencies of SNPs within the population. However, in our
previous study, in which we had a larger sample collec-
tion, we compared the frequencies of SNPs within the
three Zhuzes and found no significant differences in
SNPs between Zhuzes [7]. Thus, we concluded that we
could combine all samples in one sample collection.
Genotyping of 158 SNPs from 320 DNA samples
showed that 75 SNPs were not found in the studied
samples (Table 1, Additional file 2). The frequencies of
many of these SNPs were very low in other populations
as well [10]. However, we could not conclude that these
SNPs did not occur (or were only present in a very low
frequency) in the Kazakh population. In addition, seven
of 83 SNPs identified in the Kazakh population were not
in Hardy-Weinberg equilibrium. We expect that this re-
sult may have been caused by the insufficient power of
the study.
In this study, we selected SNPs involved in the ADME
of drugs for genotyping. Thus, 19 of 83 SNPs occurring
in the Kazakh population were associated with drugs
used in the treatment of cardiovascular diseases (statins,
beta-blockers, anticoagulants, and antiplatelet agents).
The recommended dosage for the cholesterol-lowering
agent simvastin is 80 mg (U.S. Food and Drug Adminis-
tration [FDA], www.fda.gov). Moreover, the FDA recom-
mends dose correction when using simvastatin with
certain drugs that cause increased concentrations of sim-
vastatin, resulting in increased risk of myopathy. In
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patients with the C allele at the SNP rs4149056 in the
SLCO1B1 gene, there are modest increases in myopathy
risk even at lower doses of simvastatin (40 mg daily); if
optimal efficacy is not achieved with a lower dose, alter-
nate agents should be considered [11]. The TT genotype
frequency in our study was 72 % in Kazakhs, compared
with 91 %, 71 %, 60 %, and 98 % in the ASW, CHB, TSI,
and YRI populations, respectively. Moreover, responses
of individuals to statin drugs are associated with ABCB1
(rs2032582), ABCC2 (rs717620), ABCG2 (rs2231142),
SLCO1B1 (rs2306283), CYP2C8 (rs10509681), and
CYP2C9 (rs1799853, rs1057910). Comparative analysis
of the frequencies of these SNPs in the Kazakh popula-
tion with those in the ASW population showed signifi-
cant differences for all SNPs, except for the SNPs in
cytochrome P450. In contrast, for the CEU population,
only the SNPs in cytochrome P450 and SLCO1B1
(rs2306283) were significantly different from those in
the Kazakh population.
The VKORC1 gene on chromosome 16 is one of the
main genes associated with the dosage of coumarin anti-
coagulants, and several mutations in this gene are asso-
ciated with enzyme deficiency. An allelic variant in
VKORC1 (c.-1639G > A) determines up to 30 % of the
variability in warfarin dosage [12, 13]. In a previous
study, the VKORC1 c.-1639G > A mutation was found to
be linked with VKORC1 c. 173 + 1369G > C (rs8050894)
and VKORC1 c. 173 + 1000C > T (rs9934438) mutations
[14]. Subjects carrying the 1173 T (rs9934438) allele re-
quired a lower maintenance dose of warfarin compared
with that in subjects harbouring the CC genotype in
African Americans and Caucasians. Before reaching the
maintenance dose, only Caucasians with the T allele had
a significantly increased risk of international normalized
ratio compared with that in Caucasians harbouring the
CC genotype. Polymorphisms in the VKORC1 gene are
associated with the maintenance dose requirements of
warfarin among both African Americans and Caucasians
[15]. Interestingly, in VKORC1, the allele frequency of
rs8050894 c. 173 + 1369G > C is as high as 94 % (G al-
lele) in Asian populations, whereas that in Caucasians is
about 37 % (G allele). In the Kazakh population, we
found that the frequency of allele G was 63 %. Import-
antly, the response to anticoagulant drugs (e.g., warfarin)
is associated with CYP1A1 (rs1048943) and CYP2C9
(rs1057910, rs28371685, and rs1799853). Comparative
analysis of the frequencies of these SNPs showed that all
of the SNPs listed above were significantly different be-
tween the Kazakh population and the YRI population,
with the exception of rs28371685. The majority of the
data were not present in the HapMap database
(Table 2).
The treatment of cardiovascular diseases often in-
volves administration of Plavix (clopidogrel). The in-
fluence of genetics on the pharmacokinetic and
pharmacodynamic response to clopidogrel has been ex-
amined in previous studies [16]. Several polymorphic
P450 enzymes are involved in the activation of clopido-
grel. The CYP2C19 isoenzyme is involved in the forma-
tion of an active metabolite and intermediate metabolite,
2-oxoclopidogrel. The pharmacokinetics and antiplatelet
effects of the active metabolite of clopidogrel, which
were investigated by means of platelet aggregation ex
vivo, vary depending on the genotype of the CYP2C19
isoenzyme. Allele CYP2C19*1 is responsible for the nor-
mally functioning metabolism, whereas alleles of the
CYP2C19*2 and CYP2C19*3 genes are responsible for
decreased metabolism. The frequency of the A
(rs4244285) allele in our study was 17 % in Kazakhs,
compared with 15.5 %, 28 %, and 14 % in CEU, JPT, and
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YRI populations, respectively. For rs4986893, the A allele
frequency in our study was 4 % in Kazakhs; no HapMap
data were available for other populations. Other alleles
associated with reduced metabolism have been identified
in CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7,
and CYP2C19*8; however, these alleles were rarely found
in our population.
The response to antiplatelet agents (Plavix) is also associ-
ated with ABCB1 (rs2032582), CYP1A1 (rs1048943),
CYP1A2 (rs762551), CYP2B6 (rs3745274), CYP2C8
(rs10509681), CYP2C9 (rs1799853), and CYP2C19
(rs12248560). Comparative analysis of SNP frequencies
showed that these SNPs were significantly different between
the Kazakh population and the YRI population, with the ex-
ception of rs2032582. The majority of data were not avail-
able in the HapMap database. Significant differences in
genes in the ATP-binding cassette system were not found
between the Kazakh and JPT populations (Table 2).
Labetalol is a nonselective β-adrenergic antagonist
with additional α1-adrenergic antagonist properties.
CYP2C19 is involved in the metabolism of several im-
portant groups of drugs, including a number of β-
blockers, such as propranolol and labetalol [17]. A
previous study showed that the activity of labetalol is
significantly affected by common CYP2C19 polymor-
phisms in individuals of Chinese ethnicity; specifically,
subjects with the CYP2C19*2/*2 (rs4244285) genotype
had a higher peak and area under the concentration-
time curve than subjects with the CYP2C19*1/*1
genotype, and heterozygotes had intermediate values
[18]. In the Kazakh population, genotype AA was
found in 2 % of individual, whereas 5.2 %, 6.8 %, and
3.4 % of individuals in the CEU, JPT, and YRI popula-
tions carried this allele.
Responses to β-blockers are associated with ABCB1
(rs1128503) and UGT1A1 (rs4148323 and rs4124874).
All of these SNPs were significantly different between
the Kazakh and YRI populations, although most data
were not available in the HapMap database. Significant
differences in genes in the ATP-binding cassette system
and UDP glucuronosyltransferase were not observed be-
tween the Kazakh and JPT populations. Moreover, SNPs
in the UGT1A1 genes did not differ between the CHD
and TSI populations (Table 2).
SNPs in ABCB1 (rs1045642) and CYP2C19
(rs4244285) are associated with the response to β-
blockers, anticoagulants, and antiplatelet agents. Import-
antly, the frequencies of these SNPs were significantly
different between the Kazakh population and the ASW,
CEU, GIH, MKK, and YRI populations for rs1045642
and between the Kazakh population and the CHB and
JPT populations for rs4244285 (Table 2).
Analysis of the results of haplotype frequencies among
the populations examined in this study showed
substantial and significant variations. For example, only
four populations generated the block in the SLCO1B3
gene, similar to the Kazakh population. The CHB popu-
lation had the most similar haplotype frequency com-
pared with the Kazakh population. However, there were
variations in haplotypes among populations, with differ-
ences in GA, TG, and TA haplotypes for the CHB and
in GA, TG, and GG haplotypes in the Kazakh popula-
tion. Only eight populations generated blocks in the
NAT2 gene, and 24 haplotypes were formed by the ana-
lysed SNPs. From these results, none of the examined
populations were similar to the Kazakh population with
regard to this gene. However, all 11 populations gener-
ated haplotype blocks in UGT2B7 and SLC15A2 genes,
and the CEU population had the closest frequency for
UGT2B7, whereas the YRI population had the closest
frequency for SLC15A2 relative to the Kazakh popula-
tion. Thus, for these three genes (UGT2B7, SLC15A2,
and SLCO1B3), the Kazakh population showed similar-
ities with three different populations. All three of these
populations showed significant differences in these three
genes.
Conclusion
In summary, our data provided important information
for personalised medicine in the Kazakh population,
supporting the genotyping of specific SNPs before ad-
ministration of drugs with respect to the patient’s ethni-
city. The allele frequencies of the studied SNPs were
quite different in the Kazakh population compared with
those for all of the other populations examined. More-
over, we could not classify the Kazakh population as
Asian or Caucasian, indicating that the Kazakh popula-
tion may have been formed from several populations be-
longing to different racial groups.
Our study had several limitations. First, we had only a
small number of samples. In addition, it will be useful to
perform comparative analysis of the frequencies of SNPs
in the different Zhuzes in order to clarify that combining
samples from all Zhuzes is acceptable. Unfortunately, in
this study, we did not have sufficient data to classify in-
dividuals into Zhuzes, only by nationality. In future stud-
ies, we plan to increase the number of samples and to
examine additional SNPs.
Methods
Characteristics of the study populations
A total of 320 individuals living in Astana during 2012–
2013 and belonging to the Kazakh nationality participated
in this study. All individuals included in the present study
were unrelated and randomly selected from different re-
gions of Kazakhstan. The mean (± standard deviation
[SD]) age of the participants was 44.06 ± 17.98 years (age
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range: 19–86), and the population included 239 men and
81 women.
Blood samples were collected in clinics in the city of
Astana (Republican research center of transfusion,
National research cardiac surgery center and Medical
center of the Presidential Administration of Kazakhstan).
Blood samples were taken according to the study proto-
col, which was approved by the Ethics Committee of the
National Center for Biotechnology of the Republic of
Kazakhstan, Astana, Kazakhstan (No. 11, 14.02.2010),
Republican research center of transfusion, National re-
search cardiac surgery center and Medical center of the
Presidential Administration of Kazakhstan.
Each participant was informed of the purpose and
methods of the study, and written informed consent was
obtained from all participants. Each volunteer filled out
a questionnaire to collect standard personal data, includ-
ing their nationality and the nationalities of their parents
and grandparents. Based on the concept of Zhety ata, in
which each Kazakh individual is expected to know seven
generations of their ancestors, we were able to collect in-
formation on nearly seven generations from each volun-
teer. While the questionnaire included data only to the
second generation, the ethnicities of ancestors from the
third to seventh generations were determined according
to a verbal survey. If an individual indicated that he or
she had an ancestor who was not a Kazakh, the blood
sample from this individual was excluded.
Genotyping
DNA was collected from whole venous blood samples
collected in EDTA-containing tubes. DNA from blood
was extracted by the salting-out method [19], and geno-
typing was performed using real-time polymerase chain
reaction (PCR) with high-throughput OpenArray tech-
nology. Amplification was performed on a QuantStudio
12 K Flex thermocycler (Life Technologies, USA) using
pharmacogenomic PGx panels. The composition of the
PCR mixture was as follows: OpenArray Genotyping
Master Mix (2.5 μL/sample) and DNA sample of 50 ng/
μL (2.5 μL/sample). The reaction volume was 5 μL. Each
reaction mixture was covered by immersion oil. The
PCR conditions were as follows: 10 min at 93°С; 50 cy-
cles of 45 s at 93°С, 13 s at 94°С, and 2.14 min at 53.5°С;
and incubation at 25°С for 2 min. Data processing was
carried out using TaqMan Genotyper Software v. 1.3.
Statistical analysis
Statistical analysis was performed using Haploview 4.2
[20] and Arlequin 3.1 [21] software. The correspondence
of the distributions of genotype frequencies to the
Hardy-Weinberg equilibrium was assessed using the χ2
criterion (preliminary analysis) and exact tests using a
Markov chain. Data from the HapMap database were
used for the comparative analysis of the differences in
genotype and haplotype frequencies among Kazakh and
world populations (HapMap Genome Browser release
#27 [Phases 1, 2, & 3 - merged genotypes and frequen-
cies]) [10]. The exact test of population differentiation
(Markov chain) method was used for the analysis [9, 21].
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